# Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder

> **NCT06086275** · PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 18 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Buprenorphine

## Key facts

- **NCT ID:** NCT06086275
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-04
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086275, "Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06086275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*